Vesalius
Biocapital IV

Vesalius
Biocapital IV

We are investing in appealing, later-stage companies in drug development, medical devices & diagnostics and eHealth / mHealth, predominantly in Europe. Our portfolio companies address unmet medical & market needs and operate on the basis of strong intellectual property protection.

Latest news

ENYO PHARMA announces completion of series C financing with VESALIUS BIOCAPITAL

HepaRegeniX Doses First Patient in Phase Ib Trial with Small Molecule Inhibitor HRX-215 to Promote Liver Regeneration

Inflammatix Raises $57M in Series E Financing